NBY novabay.com: Company Short-Term Debts

NBY (novabay.com) - company brandmark

NovaBay Pharmaceuticals (NBY) faces risks associated with declining margins for ophthalmology products and debt leverage, as evidenced by the shift in short-term liabilities on the GURU.Markets daily price chart, where the indicator stands at -0.02. Business stability relies on demand within the pharmacy segment, while management optimization and strict cost controls help minimize current operational threats.

NovaBay (NBY) - Company Short-Term Loans and Borrowings from 07/04/2022 to 04/18/2026

Analytical breakdowns and data insights for company NovaBay Pharmaceuticals Inc. (NBY)

- current quotes and average value forecast:
Price Chart NovaBay|NBY - Consensus Target
- company stock capitalization data:
Market Capitalization NovaBay Pharmaceuticals, Inc.|NBY - Enterprise Value
- business book valuation details:
Accounting Value per Share NovaBay Pharmaceuticals|NBY - Accounting Value of Company|Market Capitalization to Book Value Ratio novabay.com|NBY - Company Assets
- debt level and financial liquidity data:
Total Debt to Equity Ratio NovaBay Pharmaceuticals|NBY - Long-Term Liabilities to Capital|Short-Term Debt to Capital NovaBay|NBY - Company Cumulative Debt|Debt to Book Capitalization Ratio NovaBay Pharmaceuticals, Inc.|NBY - Long-Term Debt Volume|Company Short-Term Debt NovaBay Pharmaceuticals|Quick Liquidity novabay.com
- earnings and valuation multiples indicators:
NBY - Company Net Income
Basic company analysis:NBY - novabay.com
Flagship merchandise of NovaBay Pharmaceuticals Inc.

Investors must weigh the growth potential of NovaBay Pharmaceuticals (NBY) against liquidity risks to avoid pitfalls in short-term planning. Monitoring current debt allows for an assessment of obligations maturing within one year, where a stable trend confirms the financial resilience of NovaBay Pharmaceuticals, supported by patent-protected chemical formulas and stable distribution channels within the pharmacy sector.

Competitors of NovaBay Pharmaceuticals

ALC - Company Short-Term Debt|Bausch & Lomb (BLCO) - Company Current Liabilities|GKOS: Company Short-Term Debts|Apellis Corp (APLS) - Company Short-Term Debts|Company Current Liabilities BLTE|OCUL: Company Short-Term Loans and Borrowings|Company Short-Term Debts HROW|VRDN - Short-Term Debt|LENZ Pharma - Company Current Liabilities|Oculis (OCS) - Short-Term Debt|EyePoint Pharmaceuticals - Company Short-Term Debts|Short-Term Debt kodiak.com|aldeyra.com (ALDX) - Company Short-Term Debt|KALA - Short-Term Debt Volume|Company Short-Term Debt Opus Genetics, Inc.|Company Short-Term Indebtedness OKYO (OKYO Pharma Inc)|Company Short-Term Debt Adverum Biotechnologies (ADVM)|OTLK - Short-Term Debt|Clearside Biomedical, Inc. - Company Current Liabilities|Kiora Pharmaceuticals Inc. - Company Short-Term Debt|Alimera - Company Short-Term Debts|EYEN - Company Short-Term Debts|GHSI: Company Short-Term Debts|OCUP (ocuphire.com) - Company Short-Term Debt|OPT (Opthea) - Company Short-Term Debts